Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Partner
Lundbeckfond Ventures - Copenhagen, Denmark
Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA
Manager, Strategic Forecasting & Analytics Job
Celgene Corporation - Basking Ridge, NJ, US

More Jobs >>

Events

Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
Life Science in the Cloud
Nov 16, 2011 — Cambridge, MA
Just Released: New Trends in Preventive and Therapeutic Vaccine
Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston

More Events >>

Related Tags >> Vaccine Tamiflu H5N1

Relenza News

Most Popular Relenza Story

Relenza outperforms Tamiflu in bird flu study

May 22, 2008 — 5:59am ET

The antiviral Relenza has won a battle over Tamiflu in the competition for government contracts from governments anxious about a possible bird flu epidemic. New research published in Nature Read more...

Relenza Press Releases

Biota Announces Relenza Royalty for March 2011 quarter
Ample Supplies of Relenza Available as Flu Season Peaks
GSK Ready to Supply RELENZA(R) to Meet New CDC Interim Recommendations this Flu Season
GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)

Latest Headlines

Relenza outperforms Tamiflu in bird flu study
May 22, 2008

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK